Synergy Rx Pharmacy Issues Recall Due to Lack of Sterility

News
Article

The company has voluntarily recalled all lots of of human chorionic gonadotropin because of a lack of sterility assurance.

On Feb. 14, 2017, Synergy Rx Pharmacy announced a voluntary recall of all lots of of human chorionic gonadotropin  (HCG) 5000 units/vial and 11,000 units/vial, distributed between June 1, 2016 and Dec. 22, 2016, because of a lack of sterility assurance. The recalled lots, which were packaged in 15 mL serum glass vials, were distributed to physician offices and clinics in Arizona, California, Wisconsin, and Minnesota.

As of Feb. 14, the company had not received any reports of adverse events due to the recalled product but it warns that use a product intended to be sterile that is not sterile could result in serious infections. The company is advising customers to stop use of the product and return any unused lots. Adverse events can be reported to FDA at www.fda.gov/medwatch/report.htm.

Source: FDA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments